Home › Research › Disparities
Disparity of Prescribed Psychotropics in Alzheimer’s Disease with Neuropsychiatric Symptoms
Samuel I Nathaniel, Maggie Oliver, Thomas I. Nathaniel, Laurie Theriot Roley, Richard L. Goodwin, Adebobola Imeh‐Nathaniel. Pharmacoepidemiology, 2025-12-22
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
A total of 7031 AD patients were identified. Overall, 6237 patients were NHWs, and 794 were NHBs. Among the NHW AD patients, 1909 presented with behavioral disturbances or neuropsychiatric symptoms (NPS), and 168 NHB AD patients presented with NPS. In the adjusted analysis, NHW ADNPS patients were more likely to be treated with galantamine (OR = 1.538, 95% CI, 1.001–2.364, p = 0.049), memantine (OR = 1.222, 95% CI, 1.086–1.375, p < 0.001), olanzapine (OR = 2.323, 95% CI, 1.794–3.009, p < 0.001), risperidone (OR = 4.181, 95% CI, 3.539–4.939, p < 0.001), and escitalopram (OR = 1.401, 95% CI, 1.225–1.602, p < 0.001). In contrast, NHB ADNPS patients were more likely to be treated with memantine (OR = 2.601, 95% CI, 1.746–3.875, p < 0.001) and risperidone (OR = 5.526, 95% CI, 3.411–8.951, p < 0.001). Our findings show the use of memantine and risperidone to treat both NHB and NHW ADNPS patients. NHW ADNPS patients were more likely to be treated with galantamine, memantine, olanzapine, risperidone, and escitalopram. In contrast, NHB patients with ADNPS were more likely to be treated with memantine and risperidone.
What this study adds
Evidence grade: Low
The record lists 6,237 participants. Among 7031 Alzheimer's disease patients, those with neuropsychiatric symptoms were prescribed different psychotropic medications depending on whether they were non-Hispanic White or non-Hispanic Black. Reported effect size: OR = 1.538; OR = 1.222; OR = 2.323.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nathaniel, S. I., Oliver, M., Nathaniel, T. I., Roley, L. T., Goodwin, R. L., & Imeh‐Nathaniel, A. (2025). Disparity of Prescribed Psychotropics in Alzheimer’s Disease with Neuropsychiatric Symptoms. Pharmacoepidemiology. https://doi.org/10.3390/pharma5010001
Vancouver
Nathaniel SI, Oliver M, Nathaniel TI, Roley LT, Goodwin RL, Imeh‐Nathaniel A. Disparity of Prescribed Psychotropics in Alzheimer’s Disease with Neuropsychiatric Symptoms. Pharmacoepidemiology. 2025. doi:10.3390/pharma5010001.
BibTeX
@article{nathaniel2025-eff6a280,
author = {Nathaniel, Samuel I and Oliver, Maggie and Nathaniel, Thomas I. and Roley, Laurie Theriot and Goodwin, Richard L. and Imeh‐Nathaniel, Adebobola},
title = {{Disparity of Prescribed Psychotropics in Alzheimer’s Disease with Neuropsychiatric Symptoms}},
journal = {Pharmacoepidemiology},
year = {2025},
doi = {10.3390/pharma5010001},
url = {https://doi.org/10.3390/pharma5010001}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- A total of 7031 AD patients were identified.
- Overall, 6237 patients were NHWs, and 794 were NHBs.
- Among the NHW AD patients, 1909 presented with behavioral disturbances or neuropsychiatric symptoms (NPS), and 168 NHB AD patients presented with NPS.
- In the adjusted analysis, NHW ADNPS patients were more likely to be treated with galantamine (OR = 1.538, 95% CI, 1.001–2.364, p = 0.049), memantine (OR = 1.222, 95% CI, 1.086–1.375, p < 0.001), olanzapine (OR = 2.323, 95% CI, 1.794–3.009, p < 0.001), risperidone (OR = 4.181, 95% CI, 3.539–4.939, p < 0.001), and escitalopram (OR = 1.401, 95% CI, 1.225–1.602, p < 0.001).
- In contrast, NHB ADNPS patients were more likely to be treated with memantine (OR = 2.601, 95% CI, 1.746–3.875, p < 0.001) and risperidone (OR = 5.526, 95% CI, 3.411–8.951, p < 0.001).
Why it matters
Among 7031 Alzheimer's disease patients, those with neuropsychiatric symptoms were prescribed different psychotropic medications depending on whether they were non-Hispanic White or non-Hispanic Black. This describes disparities in prescribing patterns, not the effectiveness of any treatment for the disease.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Participants6,237
- Effect sizeOR = 1.538; OR = 1.222; OR = 2.323
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Pharmacoepidemiology) |
| Journal's citation record | 0 / 4 | Pharmacoepidemiology: journal h-index 31 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 6,237 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Adebobola Imeh‐Nathaniel: h-index 8 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of South Carolina: institution h-index 712 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Related studies in Disparities from nearby years
Also in Disparities
98 studies in the library are filed under Disparities with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disparities hub.